Review Article

Antibody Immunodeficiency Diseases

Authors: Joseph Trent Ellenburg, DO, Richard D. deShazo, MD

Abstract

Among primary immunodeficiencies, antibody deficiencies are the most common. Patients often are examined first by multiple medical providers by whom the diagnosis may be missed or delayed, because signs and symptoms are usually sinopulmonary in
origin, simulate common respiratory infections or respiratory allergies, and are usually responsive to symptomatic antimicrobial treatment. Because these diseases can be treated effectively, it is important to recognize them before complications occur. We have provided updated information on the more common antibody deficiency syndromes, their diagnostic assessment, and advances in treatment.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. International Union of Immunological Societies. Primary immunodeficiency diseases: report of an IUIS Scientific Committee. Clin Exp Immunol 1999; 118:1-28.
 
2. Woo CK, Bahna SL. Evaluation of the child with immunodeficiency disorder. Pediatr Ann 2011;40:205-211.
 
3. Coico R, Sunshine G, Benjamini E.Immunology. A Short Course. 5th ed. Hoboken, NJ: John Wiley & Sons; 2003.
 
4. Alqudah M, Graham SM, Ballas ZK. High prevalence of humoral immunodeficiency patients with refractory chronic rhinosinusitis. Am J Rhinol Allergy 2010;24:409-412.
 
5. Uzzaman A, Fuleihan RL. Approach to primary immunodeficiency. Allergy Asthma Proc 2012;33:91-95.
 
6. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92:34-48.
 
7. Hermaszewski RA, Webster AD. Primary hypogammaglobulinemia: a survey of clinical manifestations and complications. Q J Med 1993;86:31-42.
 
8. Wood P, Stanworth S, Burton J, et al. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol 2007;149:410-423.
 
9. Sorensen RU, Moore C. Antibody deficiency syndromes. Pediatr Clin North Am 2000;47:1225-1252.
 
10. Reda S, El-Ghoneimy D, Afifi H. Clinical predictors of primary immunodeficiency diseases in children.Allergy Asthma Immunol Res2013;5:88-95.
 
11. Notarangelo L. Primary immunodeficiencies. J Allergy Clin Immunol 2010; 125:S182-S194.
 
12. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94:S1-S63.
 
13. Litzman J, Burianova M, Thon V, et al. Progression of selective IgA deficiency to common variable immunodeficiency in a 16 year old boy. Allergol Immunopathol (Madr) 1996;24:174-176.
 
14. Liblau RS, Bach JF. Selective IgA deficiency and autoimmunity. Int Arch Allergy Immunol 1992;99:16-27.
 
15. Munks R, Booth JR, Sokol RJ. A comprehensive IgA service provided by a blood transfusion center. Immunohematology 1998;14:155-160.
 
16. Driessen G, van der Burg M. Educational paper: primary antibody deficiencies. Eur J Pediatr 2011;170:693-702.
 
17. Hammarstrom L, Vorechovsky I, Webster D. Selective IgA deficiency (SigAD) and common variable immunodeficiency (CVID). Clin Exp Immunol 2000;120:225-331.
 
18. Etzion A. Immune deficiency and autoimmunity. Autoimmun Rev 2003;2:364-369.
 
19. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009;145:709-727.
 
20. Webster DB. Common variable immunodeficiency. Humoral immunodeficiencies. Immunol Allergy Clin North Am 2001;21:1-22.
 
21. Cunningham-Rundles C. Common variable immunodeficiency. Curr Allergy Asthma Rep 2001;1:421-429.
 
22. Papadopoulou-Alataki E, Hassan A, Davies EG. Prevention of infection in children and adolescents with primary immunodeficiency disorders.Asian Pac J Allergy Immunol 2012;30:249-258.
 
23. Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies. A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol 2010;135:255-263.
 
24. Tarzi MD, Grigoriadou S, Carr SB, et al. Clinical immunology review series: an approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol 2009;155:147-155.
 
25. Ochs HD, Stiehm ER, Winkelstein JA, et al. Antibody deficiencies. In: Immunological Disorders in Infants and Children. 5th ed. Philadelphia:Elsevier; 2004.
 
26. Lemmon JK, Knutsen A. IgG subclass deficiency. http://www.uptodate.com/contents/igg-subclass-deficiency?source=search_result&search=IgG+subclass+deficiency&selectedTitle=1~24. Published April 2013. Accessed December 8, 2013.
 
27. Umetsu DT, Ambrosino DM, Geha RS. Children with selective IgG subclass deficiency and recurrent sinopulmonary infection: impaired response to bacterial capsular polysaccharide antigens. Monogr Allergy 1986;20:57-61.
 
28. Soderstrom T, Soderstrom R, Avanzini A, et al. Immunoglobulin G subclass deficiencies.Int Arch Allergy Appl Immunol 1987;82:476-480.
 
29. Buckley RH. Immunoglobulin G subclass deficiency: fact or fancy?Curr Allergy Asthma Rep 2002;2:356-360.
 
30. Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins-understanding properties and mechanisms. Clin Exp Immunol 2009;158:2-13.
 
31. Wilson CB, Lewis DB, Penix LA. The physiologic immunodeficiency of immaturity. In: Immunological Disorders in Infants and Children. Philadelphia: WB Saunders; 1996.
 
32. Bonilla F. Antibody deficiency. In: Leung DYM, Sampson H, Geha R, et al, eds. Pediatric Allergy: Principles and Practice. Philadelphia:Mosby; 2003:88-98.
 
33. Ballow M, Cates KL, Rowe JC, et al. Development of the immune system in very low birth weight (less than 1500 g) premature infants; concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res 1986;20:899-904.
 
34. Winkelstein JA, Marino MC, Lederman HM, et al. X-linked agammaglobulinemia: a report on a United States registry of 201 patients. Medicine (Baltimore) 2006;85:193-203.
 
35. Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361:226-233.
 
36. Buckley R. Primary B-cell diseases. In: Behrman RE, Kliegman RM, Jenson HB, eds. Nelson Textbook of Pediatrics. 16th ed. Philadelphia: WB Saunders; 2000:596-599.
 
37. Cham B, Bonilla MA, Winkelstein J. Neutropenia associated with primary immunodeficiency syndromes. Semin Hematol 2002;39;107-112.
 
38. Winkelstein JA, Marino MC, Ochs H, et al. The X-linked hyper-IgM syndrome: clinical and immunological features of 79 patients. Medicine (Baltimore) 2003;82:373-384.
 
39. Conley ME, Dobbs AK, Farmer DM, et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol 2009;27:199-227.
 
40. Carneiro-Sampaio M, Coutinho A. Immunity to microbes: lessons from primary immunodeficiencies. Infect Immun 2007;75:1545-1555.
 
41. Johnson J, Filipovich AH, Zhang K. X-linked hyper-IgM syndrome. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=xlhi. Accessed January 25, 2010.
 
42. Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997;131:47-54.
 
43. Garcia JM, Gamboa P, de la Calle A, et al. Diagnosis and management of immunodeficiencies in adults by allergologists. J Invest Allergol Clin Immunol 2010;20:185-194.
 
44. Makhija M, O’Gorman MR. Common in vitro tests for allergy and immunology. Allergy Asthma Proc 2012;33:108-111.
 
45. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000;20:84-100.
 
46. Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125:1354-1360.
 
47. Kumar A, Teuber S, Gershwin M. Intravenous immunoglobulin: striving for appropriate use. Int Arch Allergy Immunol 2006;140:185-198.
 
48. Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev 2010;24:S28-S50.
 
49. Wu E, Frank M. The mystery of IVIg. Rheumatologist March 2012.
 
50. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 2011;127:315-323.
 
51. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008;26:513-533.